Companies in #Heart Failure with Preserved Ejection Fraction (HFpEF)

Kardigan is a clinical-stage cardiovascular biotechnology company founded by Tassos Gianakakos, the former CEO of MyoKardia (acquired by Bristol-Myers Squibb for $13B), with a portfolio of in-licensed cardiovascular drug candidates targeting cardiomyopathies and related heart conditions.

Tenax Therapeutics is a specialty pharmaceutical company developing therapies for pulmonary hypertension and other cardiovascular diseases with high unmet medical need. Lead candidate TNX-103 (oral imatinib) is being developed for Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a large and underserved patient population. The company has historically advanced levosimendan (TNX-101) in cardiogenic shock and has presented TNX-103 data at the 2026 ESC Congress.